Advertisement
IVF vs VNDA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVF is a Hold and VNDA is a StrongBuy.
IVF's RSI Indicator recovers from oversold territory
The RSI Oscillator for IVF moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 36 of the 41 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on IVF as a result. In 64 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for IVF just turned positive on November 04, 2026. Looking at past instances where IVF's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 190 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IVF broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IVF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.333) is normal, around the industry mean (4.142). P/E Ratio (0.001) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VNDA's RSI Indicator ascends from oversold territory
The RSI Indicator for VNDA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 26 of the 33 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 58 cases where VNDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on VNDA as a result. In 65 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for VNDA just turned positive on November 06, 2026. Looking at past instances where VNDA's MACD turned positive, the stock continued to rise in 29 of 47 cases over the following month. The odds of a continued upward trend are 62%.
Following a +13.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNDA advanced for three days, in 154 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
VNDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for VNDA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.049) is normal, around the industry mean (3.498). P/E Ratio (-0.823) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.378) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. VNDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IVF | VNDA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 73 | |
P/E GROWTH RATING 1..100 | 97 | 16 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IVF's Valuation (40) in the null industry is in the same range as VNDA (53) in the Biotechnology industry. This means that IVF’s stock grew similarly to VNDA’s over the last 12 months.
IVF's Profit vs Risk Rating (100) in the null industry is in the same range as VNDA (100) in the Biotechnology industry. This means that IVF’s stock grew similarly to VNDA’s over the last 12 months.
VNDA's SMR Rating (98) in the Biotechnology industry is in the same range as IVF (100) in the null industry. This means that VNDA’s stock grew similarly to IVF’s over the last 12 months.
IVF's Price Growth Rating (65) in the null industry is in the same range as VNDA (73) in the Biotechnology industry. This means that IVF’s stock grew similarly to VNDA’s over the last 12 months.
VNDA's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for IVF (97) in the null industry. This means that VNDA’s stock grew significantly faster than IVF’s over the last 12 months.
| IVF | VNDA | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | 3 days ago 79% |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 76% |
| Momentum ODDS (%) | 3 days ago 77% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 79% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 83% | 3 days ago 71% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 76% |
| Advances ODDS (%) | 5 days ago 83% | 7 days ago 64% |
| Declines ODDS (%) | 3 days ago 90% | 21 days ago 74% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IVF’s FA Score shows that 0 FA rating(s) are green while VNDA’s FA Score has 1 green FA rating(s).
- IVF’s FA Score: 0 green, 5 red.
- VNDA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IVF’s TA Score shows that 4 TA indicator(s) are bullish while VNDA’s TA Score has 6 bullish TA indicator(s).
- IVF’s TA Score: 4 bullish, 4 bearish.
- VNDA’s TA Score: 6 bullish, 2 bearish.
Price Growth
IVF (@Medical/Nursing Services) experienced а +21.50% price change this week, while VNDA (@Biotechnology) price change was +4.45% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.37%. For the same industry, the average monthly price growth was -4.49%, and the average quarterly price growth was -5.80%.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
IVF is expected to report earnings on Nov 16, 2026.
VNDA is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Medical/Nursing Services (+1.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFSE | 43.93 | -0.16 | -0.36% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | |||
| DRUP | 68.53 | -0.26 | -0.38% |
| GraniteShares Nasdaq Select Disruptors ETF (DRUP) | |||
| GASZ | 19.96 | -0.15 | -0.75% |
| Corgi Natural Gas Power & Turbines ETF (GASZ) | |||
| GPIQ | 53.02 | -0.60 | -1.12% |
| Goldman Sachs Nasdaq-100 Premium Income ETF (GPIQ) | |||
| FOXY | 26.18 | -0.33 | -1.24% |
| Simplify Currency Strategy ETF | |||